Azenta (AZTA)
Provides sample-management products and multiomics services for life-sciences research.
Something off on this page? Send us feedback.
Sells sample repository services, automated storage systems, cryogenic tools, consumables, and GENEWIZ multiomics services to life-sciences customers. Continuing operations center on Sample Management Solutions and Multiomics, while the B Medical exit remains an unresolved portfolio simplification.
Provides life-sciences sample management and multiomics services through its continuing segments, Sample Management Solutions and Multiomics. The portfolio includes sample repository services, automated stores, cryogenic systems, automated sample tubes, consumables, instruments, controlled-rate thawing devices, gene sequencing, and gene synthesis.
Customer exposure is more U.S.-weighted than international, with work also outside the United States. Pharmaceutical, biotechnology, and life-sciences research institutions use the platform for sample integrity from procurement and storage through analysis and data support.
The current business is the Brooks Automation successor after the semiconductor automation sale and the Azenta name and ticker change. Continuing performance depends on core segment execution, multiomics demand, acquisition integration, and resolution of the B Medical Systems exit.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 5, 2026 | Evercore ISI | Target | Target: $50 | Target: $45 |
| Jan 5, 2026 | Evercore ISI | Target | Target: $33 | Target: $50 |
| Jan 5, 2026 | Evercore ISI Group | Upgrade | ||
| Dec 19, 2025 | Needham | Reiterate | Rating: —Target: $78 | Target: $44 |
| Nov 25, 2025 | Raymond James | Reiterate | Rating: —Target: — | Target: $45 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $325.8M · Total debt $54.0M · Total assets $1.88B · Shareholders' equity $1.51B
- Revenue
- $161.2M
- Operating income
- −$4.2M
- Net income
- $2.5M
HistoryDividendAnnual yield
| Institutions | 110.22% | 50.80M shares | |
|---|---|---|---|
| 258 holders · as of Jun 30, 2026 | |||
| Insiders | 2.01% | 925.2K shares | |
| 21 holders · as of Sep 16, 2026 | |||
| Adds to | 112.23% | ||
46.09M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.23%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.34% | 7.53M | as of Jun 30, 2026 |
Politan Capital Management LPInstitution | 10.03% | 4.62M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.41% | 2.49M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.06% | 1.87M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.04% | 1.86M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Ephraim Starr | officer: SVP, Gen Counsel & Secretary | +335 | $24.17 |
| May 18, 2026 | William L. Cornog | director | +10,000 | $16.38 |
| May 16, 2025 | William L. Cornog | director | +100 | $26.50 |
| May 19, 2025 | William L. Cornog | director | +4,152 | $26.98 |
| May 20, 2025 | William L. Cornog | director | +2,748 | $27.37 |
- Thermo Fisher Scientific
Broad biobanking, consumables, and genomic-tools rival
- Labcorp
Clinical-trial biorepository and sample-management services rival
- Twist Bioscience
Synthetic DNA and NGS-tools specialist
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Azenta | $33.93 | +0.53% | $1.56B | — | 60.9 | 2.5 | +12.0% |
| Thermo Fisher Scientific | $658.14 | −0.09% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Labcorp | $313.79 | −2.24% | $26.32B | 26.6 | 16.6 | 1.8 | +5.8% |
| Twist Bioscience | $168.26 | +1.47% | $10.33B | — | — | 23.9 | +23.3% |
| Median | 31.0 | 20.8 | 5.3 | +10.5% |